Skip to content
Holistic Vive

Holistic Vive

Health is the key to success and happiness

Primary Menu Holistic Vive

Holistic Vive

  • Blood Clotting Healthcare
  • Kidney Healthcare
  • Liver Healthcare
  • Liver Cancer Healthcare
  • Brain Healthcare and Neurology
  • Contact Us
    • Advertise Here
    • Privacy Policy
    • Sitemap
  • Home
  • Rebinyn

Rebinyn

Lengthy shortage forecast for Rebinyn 3,000 IU for hemophilia B
  • Blood Clotting Healthcare

Lengthy shortage forecast for Rebinyn 3,000 IU for hemophilia B

admin February 4, 2024 0

Unexpectedly high demand for the 3,000 international units (IU) vial size of Rebinyn (nonacog beta pegol) has resulted in a...

Read MoreRead more about Lengthy shortage forecast for Rebinyn 3,000 IU for hemophilia B

Recent Posts

  • Machine learning to predict immunotherapy treatment outcomes in liver cancer | Imperial News
  • AI in Liver Care Needs Vigilance and Tailoring to Population
  • Kidney Dialysis Equipment Market, In-Depth Analysis
  • KHSC expands liver cancer treatment with cutting-edge Y90 therapy
  • GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

Archives

Categories

  • Blood Clotting Healthcare
  • Brain Healthcare and Neurology
  • Kidney Healthcare
  • Liver Cancer Healthcare
  • Liver Healthcare

Visit Us

Action Academic Excellence

You may have missed

Machine learning to predict immunotherapy treatment outcomes in liver cancer | Imperial News
  • Liver Cancer Healthcare

Machine learning to predict immunotherapy treatment outcomes in liver cancer | Imperial News

admin May 18, 2025 0
AI in Liver Care Needs Vigilance and Tailoring to Population
  • Liver Healthcare

AI in Liver Care Needs Vigilance and Tailoring to Population

admin May 16, 2025 0
Kidney Dialysis Equipment Market, In-Depth Analysis
  • Kidney Healthcare

Kidney Dialysis Equipment Market, In-Depth Analysis

admin May 16, 2025 0
KHSC expands liver cancer treatment with cutting-edge Y90 therapy
  • Liver Cancer Healthcare

KHSC expands liver cancer treatment with cutting-edge Y90 therapy

admin May 16, 2025 0
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
  • Liver Healthcare

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

admin May 14, 2025 0
Copyright © All rights reserved. | CoverNews by AF themes.